Abstract: The present invention provides a chain-shortened polynucleotide wherein the proportion of a 2?-5? phosphodiester bond is up to 3% based on the whole phosphodiester bonds or a salt thereof and a pharmaceutical composition containing the same, and a method for producing the same.

Abstract: The object of the present invention is to provide a novel medicinal agent useful in the treatment or the prevention of hepatitis. The present invention is, for example, a therapeutic or preventive agent for hepatitis characterized in that it comprises a complex of a drug carrier consisting essentially of 2-O-(2-diethylaminoethyl)-carbamoyl-1,3-O-dioleoylglycerol and a phospholipid with poly(I).poly(C).

Abstract: The present invention provides a chain-shortened polynucleotide wherein the proportion of a 2′-5′ phosphodiester bond is up to 3% based on the whole phosphodiester bonds or a salt thereof and a pharmaceutical composition containing the same, and a method for producing the same.

Abstract: The present invention provides a chain-shortened polynucleotide wherein the proportion of a 2′-5′ phosphodiester bond is up to 3% based on the whole phosphodiester bonds or a salt thereof and a pharmaceutical composition containing the same, and a method for producing the same.

Abstract: A method for producing a composition including a nucleic-acid-containing complex is characterized in that two single strand nucleic acid polymers which can at least partly form double strands are separately mixed, in a single strand form, with a cationic carrier or with source materials for the cationic carrier before the cationic carrier is formed. The resulting mixture is then dispersed in water during the production process of the nucleic-acid-containing complex.

Abstract: A method for producing a composition including a nucleic-acid-containing complex is characterized in that two single strand nucleic acid polymers which can at least partly form double strands are separately mixed, in a single strand form, with a cationic carrier or with source materials for the cationic carrier before the cationic carrier is formed. The resulting mixture is then dispersed in water during the production process of the nucleic-acid-containing complex.

Abstract: The object of the present invention is to provide a pharmaceutical composition optimized for the administration of a drug, particularly a drug which is only sparingly soluble in water, by way of inhalation. The present invention is a fat emulsion for inhalational administration, or a lyophilized composition thereof, which is an o/w fat emulsion comprising fat emulsion particles essentially composed of an oil component, an emulsifying agent and a drug as dispersed in water, characterized in that the average particle diameter of said fat emulsion particles lies within the range of 5˜100 nm. With the aid of a suitable inhaler, the inhalant of the invention readily yields a mist of aerosol particles fine enough to reach the alveolus; the inhalant is well amenable to size control of the aerosol particles.

Abstract: A method for producing a composition including a nucleic-acid-containing complex is characterized in that two single strand nucleic acid polymers which can at least partly form double strands are separately mixed, in a single strand form, with a cationic carrier or with source materials for the cationic carrier before the cationic carrier is formed. The resulting mixture is then dispersed in water during the production process of the nucleic-acid-containing complex.

Abstract: An O/W medical fat emulsion for oral administration, which is capable of increasing the bioavailability of a medicine or the blood level thereof. The emulsion is composed of fat emulsion particles containing an oil component, an emulsifier and a medicine as the indispensable constituents and dispersed in water, characterized in that the average diameter of the particles in the fat emulsion ranges from 5 to 50 nm. A freeze-dried preparation of the emulsion is also included in the invention.

Abstract: The object of the invention is to provide a high-quality pharmaceutical preparation in the field of PGE.sub.1 -containing fat emulsions, which is more stable bacteriologically, thermally, and against aging than any preparation hereto fore available.The invention, thus, relates to a PGE.sub.1 -containing lyophilized composition derived from a fat emulsion comprising PGE.sub.1, an oil component, an emulsifier, and water having a pH controlled within the neutral region. Stated differently, the invention relates to a PGE.sub.1 -containing lyophilized composition characterized by comprising PGE.sub.1, an oil component, an emulsifier and designed to give a fat emulsion having a pH within the neutral region upon reconstitution with distilled water of pH 7.0.

Abstract: There is provided a method of producing an emulsion by which an emulsion consisting of uniform and microfine globules can be easily obtained with a reduced energy input as compared with the conventional technology.This method of producing an emulsion comprises applying a back pressure equal to not less than 0.2% but less than 5% of the pressure acting on the point of high-pressure emulsifying action in a high-pressure emulsification zone in the course of production of an emulsion with a high-pressure emulsification equipment. The back pressure can be obtained typically by equipping an emulsification machine with a pipeline smaller in inside diameter than the discharge line of the machine.

Abstract: Liquid dispersions are produced wherein amphotericin B, the methyl ester thereof, nystatin, trichomycin, primaricin and the like having a particle size of 10 .mu.m or less are dispersed in a suitable solvent such as physiologically acceptable saline. The dispersions are particularly useful for parenteral administration.

Abstract: A drug carrier useful for improved drug delivery upon administration comprising a fat or fatty emulsion as a core and a surface layer thereover wherein the core amounts to 30% to 65% and the surface layer amounts to 35% to 70%. The constituents of the core and surface layer are detailed together with the improved drug delivery obtained. The emulsion has a mean particle diameter less than 100 nm.

Abstract: A lyophilized preparation which releases a fat emulsion, wherein the emulsion particle has a mean diameter of 10 to 100 nm, when redissolved prior to use. This preparation is produced by adding maltose in an arbitrary stage of the production of said emulsion prior to lyophilization.

Abstract: Stable homogeneous fatty emulsions containing amphotericin B are prepared. According to one embodiment, amphotericin B is decrystallized using an acid and ethanol and then homogeneously dispersed in a lipid, following which it is emulsified.According to a second embodiment, amphotericin B crystals are kneaded until their presence can no longer be confirmed and the decrystallized amphotericin B is thereafter uniformly dispersed in a lipid and, thereafter, emulsified.